Achyut Healthcare (BSE 543499)₹8.09−0.61%Pharmaceuticals
In the Mar 2026 quarter (standalone), Achyut Healthcare reported sales of ₹4.38 Cr, up 381.3% from Mar 2025, and net profit of ₹0.07 Cr, down 46.2% year on year. For the year to Mar 2026, sales were ₹11.58 Cr and net profit ₹0.33 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 0.00 | 0.91 | 2.54 | 1.56 | 4.38 |
| Expenses | 0.14 | 0.88 | 2.48 | 1.59 | 4.38 |
| Operating Profit | −0.14 | 0.06 | 0.09 | −0.02 | 0.03 |
| OPM % | — | 5.4% | 3.1% | −0.6% | 0.5% |
| Other Income | 0.17 | 0.17 | 0.10 | 0.03 | 0.13 |
| Interest | 0.00 | 0.05 | 0.00 | 0.00 | 0.04 |
| Depreciation | 0.00 | 0.07 | 0.04 | 0.04 | 0.09 |
| Profit before tax | 0.04 | 0.12 | 0.15 | 0.00 | 0.04 |
| Tax % | 19.9% | 7.7% | 31.2% | — | 0.0% |
| Net Profit | 0.04 | 0.13 | 0.13 | 0.00 | 0.07 |
| EPS (Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.66 | 0.34 | 0.26 | 4.06 | 2.69 | 6.13 | 3.04 | 11.58 |
| Expenses | 0.67 | 0.33 | 0.27 | 4.09 | 2.98 | 6.13 | 3.26 | 11.44 |
| Operating Profit | 0.02 | 0.02 | 0.02 | −0.04 | −0.28 | 0.03 | −0.21 | 0.18 |
| OPM % | 1.5% | 3.0% | 3.7% | −0.7% | −10.1% | 0.3% | −6.6% | 1.5% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.13 | 0.58 | 0.72 | 0.91 | 0.37 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.03 | 0.15 |
| Profit before tax | 0.00 | 0.01 | 0.00 | 0.09 | 0.30 | 0.73 | 0.69 | 0.36 |
| Tax % | 299.9% | 0.0% | 0.0% | 60.0% | 25.8% | 32.4% | 22.8% | 16.2% |
| Net Profit | −0.02 | 0.02 | 0.02 | 0.05 | 0.24 | 0.51 | 0.56 | 0.33 |
| EPS (Rs) | −0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 0.26 | 6.76 | 9.38 | 16.89 | 23.63 | 24.21 |
| Reserves | −0.04 | −0.03 | 0.00 | 2.34 | 5.18 | 13.94 | 7.75 | 10.92 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 |
| Other Liabilities | 0.04 | 0.06 | 0.25 | 0.86 | 0.81 | 0.20 | 1.29 | 2.85 |
| Total Liabilities | 0.25 | 0.28 | 0.51 | 9.96 | 15.37 | 31.03 | 32.67 | 38.15 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 | 0.07 | 0.04 | 1.56 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 3.50 | 9.18 | 18.22 | 27.91 |
| Investments | 0.00 | 0.00 | 0.00 | 1.69 | 1.29 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.25 | 0.28 | 0.51 | 8.23 | 10.52 | 21.78 | 14.41 | 8.68 |
| Inventories | 0.00 | 0.00 | 0.09 | 0.12 | 0.31 | 0.05 | 0.18 | 0.42 |
| Trade receivables | 0.11 | 0.18 | 0.29 | 0.21 | 0.28 | 0.42 | 1.35 | 1.46 |
| Cash & equivalents | 0.05 | 0.02 | 0.03 | 0.27 | 0.24 | 0.38 | 1.01 | 3.30 |
| Total Assets | 0.25 | 0.28 | 0.51 | 9.96 | 15.37 | 31.03 | 32.67 | 38.15 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −0.04 | −0.03 | 0.02 | −6.95 | −0.44 | −0.35 | −4.07 | 1.14 |
| Cash from investing activity | 0.00 | 0.00 | 0.00 | −1.59 | −4.79 | −15.17 | 4.67 | −2.22 |
| Cash from financing activity | 0.00 | 0.00 | 0.00 | 8.78 | 5.20 | 15.69 | 0.00 | 3.37 |
| Net cash flow | −0.02 | −0.01 | 0.00 | 0.23 | −0.02 | 0.13 | 0.61 | 2.28 |
| Capex | 0.00 | 0.00 | 0.00 | 0.04 | 3.33 | 6.03 | 10.90 | 8.31 |
| Free cash flow | −0.04 | −0.03 | 0.02 | −7.02 | −3.76 | −6.39 | −14.97 | −7.18 |
| CFO / OP % | −300.0% | −99.9% | 100.1% | 23,100.1% | 126.0% | −700.0% | 1,945.1% | 712.1% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 54 | 188 | 379 | 18 | 36 | 24 | 160 | 46 |
| Inventory days | 0 | 0 | 158 | 13 | 59 | 3 | 23 | 15 |
| Days payable | — | — | 381 | 42 | 56 | 13 | 144 | 44 |
| Cash conversion cycle | 54 | 188 | 156 | −9 | 40 | 16 | 41 | 17 |
| Working capital days | 76 | 210 | 216 | 604 | 1,257 | 1,242 | 1,169 | 91 |
| ROCE % | — | 9.7% | 4.3% | 2.1% | 2.6% | 3.3% | 2.3% | 1.2% |
For the Mar 2026 quarter, Achyut Healthcare reported sales of ₹4.38 Cr, up 381.3% year on year and net profit of ₹0.07 Cr, down 46.2% year on year. The operating margin was 0.5%.
Achyut Healthcare's sales for the year to Mar 2026 were ₹11.58 Cr.
Net profit for the year to Mar 2026 was ₹0.33 Cr. Earnings per share over the same trailing period were ₹0.00.
Achyut Healthcare reported borrowings of ₹0.17 Cr at Mar 2026, against cash and equivalents of ₹3.30 Cr.
Cash from operations was ₹1.14 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹7.18 Cr.